Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

套细胞淋巴瘤 伊布替尼 移植 医学 干细胞 随机对照试验 背景(考古学) 自体干细胞移植 肿瘤科 一线治疗 内科学 淋巴瘤 化疗 生物 白血病 慢性淋巴细胞白血病 古生物学 遗传学
作者
Martin H. Dreyling,Jeanette K. Doorduijn,Eva Giné,Mats Jerkeman,Jan Andrzej Walewski,Martin Hutchings,Ulrich Mey,Jon Riise,Marek Trněný,Vibeke K. J. Vergote,Daniela Donnarumma,Ofer Shpilberg,María Gomes da Silva,Sirpa Leppä,Linmiao Jiang,Christiane Pott,Wolfram Klapper,Christian Schmidt,Michael Unterhalt,Marco Ladetto
出处
期刊:Blood [Elsevier BV]
卷期号:144 (Supplement 1): 240-240 被引量:26
标识
DOI:10.1182/blood-2024-200735
摘要

On behalf of the European MCL Network, ML and EH contributed equally Introduction: In younger patients with mantle cell lymphoma (MCL), the addition of ibrutinib during induction immuno-chemotherapy and as 2-years maintenance with and without autologous stem cell transplantation (ASCT) has shown high efficacy in the 3-arm randomized TRIANGLE trial (Dreyling et al., Lancet 2024), establishing a new standard of care induction treatment and maintenance. However, the efficacy comparison of the two ibrutinib-containing treatment arms with and without ASCT was still ongoing. With prolonged follow-up, we now aim to clarify the role of ASCT in the context of ibrutinib-containing treatment, to confirm the previously observed treatment effects and to perform overall survival (OS) comparisons. Patients and methods: In 2016, the European MCL Network initiated the randomized, open-label, 3-arm TRIANGLE trial to evaluate the addition of ibrutinib to standard treatment with ASCT (arm A+I) in comparison to the previous standard treatment (arm A) and an ibrutinib-containing treatment without ASCT (arm I). Patients with previously untreated, advanced stage II-IV MCL, up to 65 years, and suitable for high-dose cytarabine and ASCT, were randomized 1:1:1 to the 3 trial arms in 13 European countries and Israel. Study treatment consisted of 6 alternating cycles of R-CHOP and R-DHAP without (arm A) or with ibrutinib added to R-CHOP cycles and as 2 years maintenance (arms A+I, I). ASCT was planned for patients of arms A and A+I responding to induction therapy. Rituximab maintenance was recommended to be applied according to national guidelines in responding patients of each trial arm. For the primary outcome, failure-free survival (FFS), stable disease at the end of induction, progression, or death were counted as events. Three pairwise log-rank tests for FFS were monitored with regular pre-planned interim analyses, each maintaining a one-sided 1.67% significance level. A pre-defined decision criterion based on the statistical significance of the treatment comparisons for FFS was established to determine the future treatment recommendation. In 2022, arm A had failed to show FFS-superiority over I and FFS in arm A+I was shown to be superior to A. OS was a secondary outcome and formal pairwise OS comparisons between treatment arms were pre-planned with interim analyses based on O'Brien-Fleming boundaries to maintain pairwise two-sided 5% significance levels. Results: Between July 2016 and December 2020, 870 patients were randomized to arms A (n=288), A+I (n=292), and I (n=290). Median age was 57 years (range 27-68), 76% were male, 87% had stage IV, and 58%/27%/15% had low/intermediate/high risk MIPI. After a median follow-up of 53 months, A+I failed to show FFS-superiority over I (3-year FFS A+I: 86% vs. I: 85%; one-sided p=0.28, hazard ratio: 0.87). FFS-superiority of A over I was again not confirmed with 3-year FFS 75% (A) vs. 85% (I; one-sided p=0.9942, hazard ratio: 1.38). In contrast, the retrospectively calculated two-sided p-value on an overall 5% significance level was consistent with FFS-superiority of I over A (p=0.0102). FFS-superiority of A+I over A was again confirmed with 3-year FFS 86% (A+I) vs. 75% (A; one-sided p=0.0034, hazard ratio: 0.64). Compared with arm A (3-year OS 85%), OS was prolonged in arms A+I and I with 3-year OS of 90% in A+I (p=0.0069, hazard ratio 0.61), and 91% in I (p=0.0041, hazard ratio 0.59). Conclusions: The results confirm superiority of ibrutinib-containing treatment without ASCT (arm I) over ASCT-containing treatment without ibrutinib (arm A) in terms of both, FFS and OS. In the context of ibrutinib- and high-dose cytarabine-containing induction immuno-chemotherapy and ibrutinib maintenance, the addition of ASCT failed to show FFS superiority, while increasing toxicity during maintenance/follow-up. According to the pre-defined decision strategy, ibrutinib+R-CHOP/R-DHAP induction followed by 2 years of ibrutinib maintenance should be the new standard of care in younger MCL patients, thus ending the era of ASCT for MCL patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yangpeiyao完成签到,获得积分10
1秒前
景然有煦发布了新的文献求助10
1秒前
JackieLiu的应助被单薄的尔烟采纳,获得10
2秒前
2秒前
jieranyisheng完成签到,获得积分10
2秒前
嘻嘻完成签到,获得积分10
2秒前
Nole的应助被zzz2193采纳,获得10
3秒前
3秒前
岁月轻狂完成签到,获得积分10
4秒前
科研通AI65的应助被qianzhihe采纳,获得10
4秒前
完美世界的应助被六百六十六采纳,获得10
4秒前
5秒前
Garnieta发布了新的文献求助10
5秒前
5秒前
汉堡包的应助被二三采纳,获得10
5秒前
Maestro_S的应助被吃不饱采纳,获得10
5秒前
香蕉寄云完成签到,获得积分10
5秒前
RobiN发布了新的文献求助10
5秒前
爆米花的应助被金婷采纳,获得10
6秒前
6秒前
6秒前
科目三的应助被Charlie采纳,获得10
6秒前
菜不透完成签到,获得积分10
7秒前
7秒前
CodeCraft的应助被小趴菜采纳,获得10
8秒前
充电宝的应助被毫无默契可言采纳,获得10
8秒前
gao完成签到 ,获得积分10
9秒前
何文鑫发布了新的文献求助10
9秒前
9秒前
深情安青的应助被凡空采纳,获得10
9秒前
恶鬼灭杀发布了新的文献求助10
9秒前
10秒前
憨包发布了新的文献求助10
10秒前
喜喜发布了新的文献求助80
10秒前
Hcw0525发布了新的文献求助10
10秒前
zx的应助被zzz2193采纳,获得10
11秒前
科研通AI6.2的应助被凉笙采纳,获得10
11秒前
業業发布了新的文献求助10
11秒前
失眠柠檬完成签到 ,获得积分10
12秒前
背后迎夏完成签到 ,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188118
求助须知:如何正确求助?哪些是违规求助? 9575977
关于积分的说明 21844428
捐赠科研通 7785918
什么是DOI,文献DOI怎么找? 3435205
关于科研通互助平台的介绍 2559558
邀请新用户注册赠送积分活动 2482065